五期高分辨增强CT提升胰腺疾病病理符合率
回顾性纳入1886例病理确诊胰腺疾病患者,比较常规四期CT(n=346)与五期高分辨增强CT(n=1540)的诊断表现。结果显示五期HR-CT总体病理符合率较常规CT提高11.2%(P<0.001),且PDAC与非PDAC亚组均获益。小PDAC(≤2 cm)亚组优势更明显,病理符合率提高20.5%,提示该方案在高危患者的靶向应用价值。
要点
- 五期HR-CT较常规四期CT提升胰腺疾病总体病理符合率11.2%。
- 小PDAC(≤2 cm)病灶HR-CT病理符合率提高20.5%,对早期检出尤其有利。
- HR-CT方案可用于临床可疑胰腺病变患者的靶向增强检查。
核心结论
- 五期高分辨增强CT与胰腺疾病更高的报告级病理符合率相关,较小PDAC(≤2 cm)获益更为突出。
- 研究支持在筛选后的患者中靶向应用五期HR-CT,并需前瞻性多中心验证。
研究设计与样本
- 回顾性队列研究,纳入1886例病理确诊胰腺疾病患者,按临床指征非随机分配扫描方案。
- 常规四期CT方案(n=346)包含平扫、胰腺实质期、门静脉期、延迟期。
- 五期HR-CT方案(n=1540)包含平扫、动脉期、缩小FOV胰腺实质期、门静脉期、延迟期。
- 所有患者均接受术前增强CT扫描,以病理结果作为参考标准。
关键影像表现/征象
- 五期HR-CT在报告中与病理的一致性高于常规四期CT,提示其显示的胰腺病变特征更接近病理实际。
- 小PDAC(≤2 cm)在HR-CT中病理符合率绝对提高20.5%,提示该方案对小病灶显示能力更强。
诊断标准与关键数值
- 五期HR-CT总体报告级病理符合率较常规四期CT绝对提高11.2%(P<0.001)。
- PDAC亚组:HR-CT病理符合率90.0%,常规CT 81.0%(P<0.001)。
- 非PDAC亚组:HR-CT病理符合率62.0%,常规CT 50.3%(P=0.009)。
- 小PDAC(≤2 cm)亚组:HR-CT病理符合率82.4%,常规CT 61.9%(P=0.032)。
临床应用与阅片要点
- HR-CT的缩小FOV胰腺实质期与动脉期补充信息可能有助于提高胰腺病变尤其是小PDAC的诊断信心。
- 在临床可疑胰腺病变但常规四期CT诊断不确定的患者中,可考虑应用五期HR-CT方案。
- 五期方案增加扫描期数,应用时需评估辐射剂量并优先选择高危或诊断困难患者。
局限性
- 回顾性非随机设计,扫描方案按临床指征分配,存在潜在选择偏倚。
- 单中心研究,HR-CT方案的外部适用性尚需前瞻性多中心验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to investigate the diagnostic value of five-phase high-resolution contrast-enhanced CT (HR-CT) for pancreatic diseases.
METHODS: A retrospective study involving 1886 patients with pathologically confirmed pancreatic disorders was performed with non-randomized protocol allocation according to clinical indications. All patients underwent preoperative contrast-enhanced CT scans, which were divided into two protocols: conventional four-phase CT (C-CT, including plain, pancreatic parenchymal phase, portal venous phase, and delayed phase; n = 346) and five-phase HR-CT (including plain, arterial phase, reduced field-of-view pancreatic parenchymal phase, portal venous phase, and delayed phase; n = 1540). Based on pathological findings, CT diagnostic results were categorized as accurate, erroneous, or ambiguous. Multivariate logistic regression and chi-square tests were used to compare the report-level concordance with pathology and sensitivity of the two CT protocols for pancreatic diseases.
RESULTS: HR-CT was associated with a significantly higher report-level concordance with pathology for pancreatic diseases than C-CT, with an absolute increase of 11.2% (P < 0.001). Higher report-level concordance with pathology of HR-CT over C-CT was observed in both pancreatic ductal adenocarcinoma (PDAC) and non-PDAC subgroups (PDAC: 90.0% vs. 81.0%, P < 0.001; non-PDAC: 62.0% vs. 50.3%, P = 0.009). For small PDAC lesions (≤2 cm), the report-level concordance with pathology of HR-CT was 20.5% higher than that of C-CT (82.4% vs. 61.9%, P = 0.032).
CONCLUSIONS: Five-phase HR-CT was associated with significantly higher report-level concordance with pathology for pancreatic diseases in this retrospective cohort, particularly for the detection of small PDAC (≤2 cm). Targeted use in selected patients, together with prospective multicenter validation, is warranted.
引用
- Zhan, Mao, Gao, et al. Five-phase high-resolution contrast-enhanced CT is associated with higher report-level concordance with pathology for pancreatic diseases. Eur J Radiol. 2026. PMID: 42580078. doi:10.1016/j.ejrad.2026.113139
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。